This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Assessing the relationship between health utilities, quality of life, and health care costs in Alzheimer’s disease: the CATIE-AD study


Miller, E. A., Rosenheck, R. A., Schneider, L. S.


Current Alzheimer Research, Volume: 7, No.: 4, Pages.: 348-357

Year of Publication



Objectives: To examine the relationship between multiple measures of health care costs and health utilities, quality of life, and other factors in Alzheimer’s Disease (AD).; Research Design: Data were obtained via caregiver proxy at baseline and 3- 6- and 9-months following study entry on 421 patients with AD who participated in the CATIE-AD trial of antipsychotic medication. Spearman rank correlations and mixed models (using logged costs) were used to examine the correlates of health care costs.; Measures: Health care costs include inpatient hospital, nursing home, residential care, combined institutional, outpatient, ancillary drug, and total costs. Correlates include the AD-Related Quality of Life Scale (ADRQoL) and Health Utilities Index (HUI)-III.; Results: Total monthly health care costs averaged $1,205 during the study period. Each .10 increment on the HUI-III (stronger health utilities) was associated with a decrease in institutional, outpatient, and total costs of 9.7%, 6.9%, and 8.2%, respectively. Each one-point increase on the ADRQoL (better quality of life) was associated with an increase in ancillary drug and total costs of 1.7% and 2.1%. Total costs tended to be lower for female patients (beta=-.325) with better physical functioning (beta=-.017) but higher for less cognitively impaired individuals (beta=.038). Older (beta=.025), non-Hispanic Whites (beta=.575) tended have higher outpatient costs, those with better physical functioning lower institutional costs (beta=-.019). Drug costs tended to be lower for females (beta=-.427) and higher for those with greater psychiatric symptoms (beta=.016).; Conclusion: The HUI-III findings suggest that health utilities could be combined with other known correlates of costs to inform resource allocation cost-effectiveness analyses associated with AD. The ADRQoL findings suggest that better quality of life may make it easier for caregivers to identify problems and/or to access and maintain certain types of health system contacts.;


aged, aged, 80 and over, alzheimer disease, antipsychotic agents, caregivers, delivery of health care, economics, female, health care costs, humans, institutionalisation, male, nursing homes, patient acceptance of health care, psychology, quality of life, statistics & numerical data, therapeutic use, therapy, trends

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cost and service use study

Type of Outcomes

Other, Quality of Life of Person With Dementia, Service use or cost reductions (incl. hospital use reduction, care home admission delay)

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants